Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Research analysts at Northland Capmk issued their Q2 2025 EPS estimates for Connect Biopharma in a research note issued on Tuesday, July 22nd. Northland Capmk analyst C. Byrnes anticipates that the company will post earnings of ($0.22) per share for the quarter. Northland Capmk has a "Strong-Buy" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. Northland Capmk also issued estimates for Connect Biopharma's Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.80) EPS and FY2027 earnings at ($0.75) EPS.
Separately, HC Wainwright assumed coverage on shares of Connect Biopharma in a research report on Thursday, June 12th. They issued a "buy" rating and a $7.00 target price on the stock.
View Our Latest Research Report on Connect Biopharma
Connect Biopharma Stock Down 5.5%
Shares of CNTB traded down $0.13 during mid-day trading on Thursday, reaching $2.22. The company had a trading volume of 122,465 shares, compared to its average volume of 245,203. The company's 50 day simple moving average is $1.13 and its 200 day simple moving average is $0.94. Connect Biopharma has a 1-year low of $0.51 and a 1-year high of $2.86. The company has a current ratio of 10.25, a quick ratio of 10.25 and a debt-to-equity ratio of 0.01.
Connect Biopharma (NASDAQ:CNTB - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07.
Connect Biopharma Company Profile
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Featured Stories
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
